Transition metal phosphides (TMPs) are promising anode candidates for sodium-ion batteries, due to their high theoretical specific capacity and working potential. However, the low conductivity and excessive volume variation of TMPs during insertion/extraction of sodium ions result in a poor rate performance and long-term cycling stability, largely limiting their practical application. In this paper, NiP2 nanoparticles encapsulated in three-dimensional graphene (NiP2 @rGO) were obtained from the flower-like spherical α-Ni(OH)2 by phosphating and carbon encapsulation processes. When used as a sodium-ion batteries anode material, the NiP2 @rGO composite shows an excellent cycling performance (117 mA h g-1 at 10 A g-1 after 8000 cycles). The outstanding electrochemical performance of NiP2 @rGO is ascribed to the synergistic effect of the rGO and NiP2 . The rGO wrapped on the NiP2 nanoparticles build a conductive way, improving ionic and electronic conductivity. The effective combination of NiP2 nanoparticles with graphene greatly reduces the aggregation and pulverization of NiP2 nanoparticles during the discharge/charge process. This study may shed light on the construction of high-performance anode materials for sodium-ion batteries and to other electrode materials.Electron-deficient heteroacenes that contain two tricoordinate boron atoms in their acene skeletons and planarized phenyl ether moieties at their periphery were synthesized via the borylation of silicon-bridged precursors. X-ray crystallographic analysis revealed quinoidal structures, which give rise to two-step reversible redox processes for both the reduction and oxidation. These compounds exhibit intense absorption and sharp fluorescence bands with vibronic structures in the near-infrared (NIR) region. These properties originate from the push-pull effect along the long axis of the molecule derived from the electron-donating ether moieties and the electron-accepting boron moieties. Of particular note is the NIR emission of the thienothiophene-centered heteroacene, which has a maximum at 952 nm with a narrow band width of 309 cm-1 in cyclohexane. A Franck-Condon analysis revealed the crucial role of the sterically less-hindered thienothiophene spacer in achieving this sharp emission band. Emicizumab is a recombinant, humanized bispecific monoclonal antibody that mimics the function of factor VIII (FVIII) which results in a significant reduction in the annualized bleeding rate in patients with haemophilia A (HA), however, the degree with which emicizumab corrects the coagulation defect remains unclear. The objective of this study was to predict the approximate FVIII level in severe haemophilia A patients with inhibitors on emicizumab using global haemostasis assays. Patients with moderate and mild HA in the non-bleeding state and healthy controls had FVIII levels and thrombin generation assessed. Linear regression was utilized to model the FVIII levels as a function of the thrombin generation assay parameters and to make a calibration curve of FVIII levels versus peak thrombin and endogenous thrombin potential. Patients with severe haemophilia A with inhibitors on emicizumab had thrombin generation performed in the same manner and their peak thrombin and endogenous thrombin potential results were placed on the calibration curve to calculate their FVIII Equivalency of Emicizumab by Thrombin Generation (F8EmT). All patients with severe HA with inhibitors on emicizumab had F8EmT>10%, suggesting they had been converted to a mild haemophilia phenotype. The patient's weight was inversely correlated to their F8EmT. The results from this study suggest that the F8EmT in patients with severe HA on emicizumab falls within the range of mild haemophilia which is consistent with the data noted in the emicizumab clinical trials and in vivo studies in animals.The results from this study suggest that the F8EmT in patients with severe HA on emicizumab falls within the range of mild haemophilia which is consistent with the data noted in the emicizumab clinical trials and in vivo studies in animals. Currently, there is no consensus on the superiority of any material for the restorative treatment of molars affected by molar-incisor hypomineralization (MIH). To evaluate the survival of restorations with stainless-steel crown (SSC) or composite resin (CR) in first permanent molars affected by MIH for 24months. In this retrospective cohort study, 61 CR and 54 SSC restorations placed on molars affected by MIH of patients, aged between 7 and 10, that were treated and overseen at a university dental clinic in the period of 2017-2020 were evaluated. The primary outcome was the failure-free survival time. Parametric survival models were used for data censored by interval, and the comparison between SSC and CR was performed using the hazard ratio function with a 95% confidence interval. The survival of SSC and CR restorations after 24months was 94.4% and 49.2%, respectively. This difference was influenced by the presence of previous restoration (aHR=3.4; 95% CI 1.2-9.4) and cusp involvement (aHR=4.0; 95% CI 1.5-11.2). In molars with MIH and the need for restorative treatment, SSC had a significantly higher survival rate than CR over 24months.In molars with MIH and the need for restorative treatment, SSC had a significantly higher survival rate than CR over 24 months.Multifunctional phototheranostic nanocomposites are promising for early diagnosis and precision therapy of cancer. Aim to enhance their accuracy and efficiency, in this study, we develop a single-laser excited activatable phototheranostic nanocomposite (UCNPs-D-MQ) 808 nm-excited upconverting nanoparticles (UCNPs) as the matrix programmed assembly with amphipathic compound DSPE-PEG-COOH, a near-infrared absorbing polymer DPP and the pro-photosensitizer MBQB. Selleckchem TAK-981 Upon endocytosed by cancer cells and excited by the 808 nm laser, UCNPs-D-MQ could produce high-yield reactive oxygen species (ROS) as the results of singlet oxygen generation from transferring to methylene blue, GSH depletion and ROS generation from photoactivation. It was proven both in vitro and in vivo that the nanocomposites exhibits remarkable therapeutic efficacy as well as minimal photodamage to normal cells. These results reveal UCNPs-D-MQ as a robust theranostic agent for tumor phototherapy.